Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 215,206 shares of the biopharmaceutical company's stock, valued at approximately $1,317,000. Connor Clark & Lunn Investment Management Ltd. owned about 0.36% of Vanda Pharmaceuticals at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. Quantbot Technologies LP acquired a new stake in Vanda Pharmaceuticals during the second quarter worth approximately $29,000. Ieq Capital LLC purchased a new stake in Vanda Pharmaceuticals in the 2nd quarter worth approximately $1,731,000. Allworth Financial LP acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $43,000. BlackRock Inc. acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at $46,841,000. Finally, Pallas Capital Advisors LLC purchased a new position in shares of Vanda Pharmaceuticals during the 2nd quarter worth $114,000. Hedge funds and other institutional investors own 88.14% of the company's stock.
Vanda Pharmaceuticals Stock Performance
NASDAQ:VNDA opened at $5.29 on Monday. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01. The company has a market cap of $319.85 million, a P/E ratio of -1.14 and a beta of 0.64. Vanda Pharmaceuticals Inc. has a fifty-two week low of $4.27 and a fifty-two week high of $9.94. The firm's 50 day moving average is $5.56 and its two-hundred day moving average is $6.49.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.46). The company had revenue of $50.53 million for the quarter, compared to analysts' expectations of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. Analysts expect that Vanda Pharmaceuticals Inc. will post -3 EPS for the current year.
Wall Street Analyst Weigh In
VNDA has been the topic of several analyst reports. B. Riley Financial restated a "buy" rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Wall Street Zen lowered Vanda Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, May 9th. HC Wainwright reduced their target price on Vanda Pharmaceuticals from $21.00 to $20.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a research note on Friday, July 17th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Vanda Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $13.70.
Check Out Our Latest Analysis on Vanda Pharmaceuticals
About Vanda Pharmaceuticals
(
Free Report)
Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company's research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda's mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.
Vanda's flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.
Further Reading
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
